Charity of the week: ALS Therapy Development Institute

Amyotrophic lateral sclerosis, commonly known as Lou Gehrig’s disease, is a progressive neurodegenerative ailment that attacks neurons in the brain and spinal cord and severely weakens muscles, including the diaphragm muscles that control breathing. It is invariably fatal and has no known cure. The sole approved therapy, the drug Rilutek, is only modestly effective. The ALS Therapy Development Institute (als.net) was founded in 1999 to develop therapies to slow and stop ALS. Located in Cambridge, Mass., the institute is the world’s largest ALS research center, with a unique, industrial-scale platform for testing dozens of potential therapies every year.

Each charity we feature has earned a four-star overall rating from Charity Navigator. Charity Navigator ranks not-for-profit organizations on the effectiveness of their programs, their control of administrative and fund-raising expenses, and the transparency of their operations. Four stars is the group’s highest ranking.

The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up